Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 13/20 | 1.00 |
| ▸ | MMP2 | P08253 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | G6PD | P11413 | 1/20 | 0.51 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.51 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.51 |
| ▸ | METAP2 | P50579 | 1/20 | 0.51 |
| ▸ | METAP1 | P53582 | 1/20 | 0.51 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CKS1B | P61024 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17506516 | 0.90 | SLC40A1 (0.82) | SLC40A1ALDH1A1LMNAUSP2HTT | |
| SCHEMBL30553404 | 0.86 | SLC40A1 (0.76) | SLC40A1MMP2ALDH1A1LMNAUSP2 | |
| SCHEMBL26964435 | 0.86 | SLC40A1 (0.76) | SLC40A1MMP2ALDH1A1LMNAUSP2 | |
| SCHEMBL29800803 | 0.85 | SLC40A1 (0.74) | SLC40A1ALDH1A1LMNAUSP2HTT | |
| SCHEMBL26964203 | 0.85 | SLC40A1 (0.74) | SLC40A1ALDH1A1LMNAUSP2HTT | |
| SCHEMBL11973763 | 0.85 | SLC40A1 (0.74) | SLC40A1CREBBPTDP1NFKBIAMEN1 | |
| SCHEMBL26964248 | 0.84 | SLC40A1 (0.72) | SLC40A1MMP2ALDH1A1LMNAUSP2 | |
| SCHEMBL30553444 | 0.84 | SLC40A1 (0.72) | SLC40A1MMP2ALDH1A1LMNAUSP2 | |
| SCHEMBL30925456 | 0.84 | SLC40A1 (0.72) | SLC40A1ALDH1A1LMNAUSP2HTT | |
| SCHEMBL30925584 | 0.84 | SLC40A1 (0.72) | SLC40A1TDP1GLO1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180328-A1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-06-21 | — | — | EP | claimed |
| US-20160068490-A1 | UBIQUITINATION INHIBITORS | MIDCAP FINANCIAL TRUST | 2016-03-10 | — | — | US | claimed |
| WO-2016025779-A1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-18 | — | — | WO | claimed |
| EP-3180328-B1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10040766-B2 | Ubiquitination inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| EP-3180328-A1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2675526-B1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-20160068490-A1 | UBIQUITINATION INHIBITORS | MIDCAP FINANCIAL TRUST | 2016-03-10 | — | — | US | disclosed |
| WO-2016025779-A1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| CN-103492028-A | Novel sulfonaminoquinoline hepcidin antagonists | VIFOR INT AG | 2014-01-01 | — | — | CN | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | SLC40A1 2/4885MMP2 4474/4885ALDH1A1 3570/4885 |
| US-20160068490-A1 | UBIQUITINATION INHIBITORS | MDM2, RBX1, NEDD4 | SLC40A1 4627/4885MMP2 2832/4885ALDH1A1 718/4885 |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | SLC40A1 2/4885MMP2 4474/4885ALDH1A1 3570/4885 |
| US-10040766-B2 | Ubiquitination inhibitors | MDM2, RBX1, NEDD4 | SLC40A1 4627/4885MMP2 2832/4885ALDH1A1 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.